Abstract
Background: The aim of this study was to assess the correlation between serum concentrations of cytokines and soluble cytokine receptors in breast cancer patients and the expression of estrogen and progesterone receptors in tumor cells.
Methods: The study comprised 158 female breast cancer patients before treatment and 50 healthy individuals as a reference group.
Results: The study revealed significantly higher concentrations of most cytokines in breast cancer patients compared to the reference group. Assessment of the correlation between cytokine concentrations in serum and the expression of estrogen and progesterone receptors in tumor cells showed significantly higher interleukin-8 (IL-8) concentrations in patients lacking progesterone receptors in comparison to patients with these receptors. The concentrations of cytokines and their soluble receptors as a function of the expression of estrogen and progesterone receptors were also analyzed in two age groups. In younger patients, aged 50years and below, no significant differences were found between serum cytokine concentrations and the expression of both estrogen and progesterone receptors. In patients older than 50years, significantly higher IL-8 concentrations were observed in individuals lacking progesterone receptors, whereas IL-1ra was significantly higher in those lacking estrogen receptors.
Conclusions: IL-1ra and IL-8 concentrations in serum, together with a lack of estrogen and progesterone receptors in tumor cells, in breast cancer patients older than 50years could represent additional predictive factors for this disease.
Clin Chem Lab Med 2006;44:1092–7.
References
1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57.10.1016/S0092-8674(00)81683-9Search in Google Scholar
2. Bachelot T, Ray-Coquad I, Menetrier-Caux C, Rasthka M, Duc A, Blay J-Y. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 2003; 88:1721–6.10.1038/sj.bjc.6600956Search in Google Scholar PubMed PubMed Central
3. Bozcuk H, Uslu G, Samur M, Yildiz M, Ozben T, Ozdogan M, et al. Tumor necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine 2004; 27:58–65.10.1016/j.cyto.2004.04.002Search in Google Scholar PubMed
4. Boumater Steege JC, Beaten CI, Thijssen VL, Satijn SA, Verhoeven IC, Hillen HF, et al. Angiogenic profile of breast carcinoma determines leukocyte infiltration. Clin Cancer Res 2004; 10:7171–8.10.1158/1078-0432.CCR-04-0742Search in Google Scholar PubMed
5. Purohit A, Newman SP, Reed MJ. The role of cytokines in regulating estrogen synthesis: implications for the etiology of the breast cancer. Breast Cancer Res 2002; 4:65–9.10.1186/bcr425Search in Google Scholar PubMed PubMed Central
6. Reed MJ, Purohit A. Breast cancer and the role of cytokines in regulating estrogen synthesis: an emerging hypothesis. Endocr Rev 1997; 18:701–15.10.1210/edrv.18.5.0314Search in Google Scholar PubMed
7. Hanma S, Shimodaira K. The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells. Endocrine J 2002; 49:371–7.10.1507/endocrj.49.371Search in Google Scholar PubMed
8. Pantschenko AG, Pushkar I, Anderson KH, Wang Y, Miller LJ, Kurtzman SH, et al. The interleukin-1 family cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol 2003; 23:269–84.10.3892/ijo.23.2.269Search in Google Scholar
9. Nikolic-Vukosavljevic D, Kanjer K, Neskovic-Konstantynovic Z, Vukotic D. Natural history of estrogen receptor-negative, progesterone receptor-positive breast cancer. Int J Biol Markers 2002; 17:196–200.10.1177/172460080201700309Search in Google Scholar PubMed
10. Floiras JL, Hacene K, Turpin F, Spyratos F. Is adjuvant tamoxifen recommended in post-menopausal node-negative breast cancer patients with hight estrogen receptor values? Int J Biol Markers 2000; 15:135–8.10.1177/172460080001500202Search in Google Scholar
11. Pienkowski T. Predictive factors in breast cancer patients. Nowotwory J Oncol 2000; 50:165–70.Search in Google Scholar
12. Freud A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A, et al. IL-8 expression and its possible relationship with esrtogen-receptor-negative status of breast cancer cells. Oncogene 2003; 22:256–65.10.1038/sj.onc.1206113Search in Google Scholar PubMed PubMed Central
13. Miller LJ, Kurtzman SH, Anderson K, Wang Y, Stankus M, Renna M, et al. Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Invest 2000; 18:293–302.10.3109/07357900009012171Search in Google Scholar PubMed
14. Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J. Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis. Int J Cancer 2002; 100:463–71.10.1002/ijc.10496Search in Google Scholar PubMed
15. Kaminska J, Nowacki MP, Kowalska M, Rysinska A, Chwalinski M, Fuksiewicz M, et al. Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I – an independent prognostic factor. Tumor Biol 2005; 26:186–94.10.1159/000086951Search in Google Scholar PubMed
16. Kaminska J, Kowalska M, Nowacki M, Chwalinski M, Rysinska A, Fuksiewicz M. CRP, TNFα, IL-1ra, IL-6, IL-8 and IL-10 in blood serum of colorectal cancer patients. Pathol Oncol Res 2000; 6:38–41.10.1007/BF03032656Search in Google Scholar PubMed
17. Balsari A, Maier JA, Colnaghi MI, Menad S. Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma. Lab Invest 1999; 79:897–902.Search in Google Scholar
18. Coskun U, Gunel N, Toruner FB, Sancak B, Onuk E, Bayram O, et al. Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer. Neoplasma 2003; 50:41–6.Search in Google Scholar
19. Heer K, Kumar H, Read JR, Monson JR, Kerin MJ. Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin Cancer Res 2001; 7:3491–4.Search in Google Scholar
20. Wu Y, Saldana L, Chillar R, Vadgama JV. Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment. Int J Oncol 2002; 20:509–16.10.3892/ijo.20.3.509Search in Google Scholar
21. Pichon MF, Moulin G, Pallud C, Pecking A, Floiras JL. Serum bFGF (basic fibroblast growth factor) and CA 15.3 in the monitoring of breast cancer patients. Anticancer Res 2000; 20:1189–94.Search in Google Scholar
22. Terasowa P, Kvasnicka J, Umlaufowa A, Homolkowa H, Jirsa M, Tesar V. Soluble TNF and IL-2 receptors in patients with breast cancer. Med Sci Monit 2000; 6:661–7.Search in Google Scholar
23. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001; 61:5407–14.Search in Google Scholar
24. Fontanini G, Campani D, Roncella M, Cecchetti D, Calvo S, Toniolo Basolo F. Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma. Br J Cancer 1999; 80:579–84.10.1038/sj.bjc.6690394Search in Google Scholar PubMed PubMed Central
25. Robinson EK, Sneige N, Grimm EA. Correlation of interleukin 6 with interleukin 1α in human mammary tumors, but not with oestrogen receptor expression. Cytokine 1998; 10:970–6.10.1006/cyto.1998.0379Search in Google Scholar PubMed
26. Pantschenko AG, Pushkar I, Miller LJ, Wang YP, Anderson K, Peled Z, et al. In vitro demonstration of breast cancer tumor cell subpopulations based on interleukin-1/tumor necrosis factor induction of interleukin-8 expression. Oncol Rep 2003; 10:1011–7.Search in Google Scholar
27. Lin Y, Huang R, Chen L, Li S, Shi Q, Jordan C, et al. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer 2004; 109:507–14.10.1002/ijc.11724Search in Google Scholar PubMed
28. Chelouche-Lev D, Miller CP, Tellez C, Runiz M, Bar-Eli M, Price JE. Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy. Eur J Cancer 2004; 40:2509–18.10.1016/j.ejca.2004.05.024Search in Google Scholar PubMed
29. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, et al. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer 2004; 90:153–9.10.1038/sj.bjc.6601517Search in Google Scholar PubMed PubMed Central
30. Elkin M, Orgel A, Kleinman HK. An angiogenic switch in breast cancer involves estrogen and soluble vascular endothelial growth factor receptor 1. J Natl Cancer Inst 2004; 96:875–6.10.1093/jnci/djh140Search in Google Scholar PubMed
©2006 by Walter de Gruyter Berlin New York
